<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163147">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936896</url>
  </required_header>
  <id_info>
    <org_study_id>HM15342</org_study_id>
    <nct_id>NCT01936896</nct_id>
  </id_info>
  <brief_title>Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction</brief_title>
  <acronym>VCU-Alpha1RT</acronym>
  <official_title>Alpha-1 Anti-Trypsin (AAT) to Quench the Acute Inflammatory Response in ST-segment Elevation Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: IRB Panel D, Virginia Commonwealth University</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarction is characterized by an intense inflammatory response.

      The degree of the response influences clinical outcome, with 'more' inflammation promoting
      heart failure. In this study we plan to determine whether treatment with plasma derived
      alpha-1 antitrypsin will quench the inflammatory response in patients with acute ST-segment
      elevation myocardial infarction (STEMI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>C reactive protein</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the curve for C reactive protein (CRP) drawn at admission, 3 days and 14 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-systolic volume change</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will calculate the interval change between admission and 3 months in left ventricular end-systolic volume, using echocardiography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>We will record the number of participants with all adverse events (cardiac and non-cardiac) over the 3 months, including infusion reactions and drug-related issues.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Alpha-1 anti-trypsin (AAT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will use plasma derived AAT 60 mg/Kg, single infusion, within 12 hours of hospital admission for ST-segment elevation myocardial infarction (STEMI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha 1-Antitrypsin</intervention_name>
    <arm_group_label>Alpha-1 anti-trypsin (AAT)</arm_group_label>
    <other_name>Prolastin C</other_name>
    <other_name>Aralast NP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and
             ECG evidence of ST segment elevation (&gt;1 mm) in 2 or more anatomically contiguous
             leads that is new or presumably new

          -  Planned or completed coronary angiogram for potential intervention

          -  Age&gt;21

        Exclusion Criteria:

          -  Inability to give informed consent

          -  Hemodynamic instability as defined as need for inotropic or vasoactive agents, or
             need for mechanical support devices (including intra-aortic balloon pump)

          -  Pregnancy

          -  Preexisting congestive heart failure (AHA/ACC class C-D, New York Heart Association
             III-IV)

          -  Preexisting severe left ventricular dysfunction (EF&lt;20%)

          -  Preexisting severe valvular heart disease

          -  Known active infections (acute or chronic)

          -  Recent (&lt;14 days) or active use of anti-inflammatory drugs (not including NSAIDs or
             corticosteroids used for IV dye allergy only)

          -  Known chronic inflammatory disease (including but not limited to rheumatoid
             arthritis, systemic lupus erythematosus)

          -  Known active malignancy of any type, or prior diagnosis in the past 10 years

          -  Anticipated need for cardiac or major surgery

          -  Known active cancer (or prior diagnosis of cancer within the past 10 years)

          -  Known Immunoglobulin A (IgA) deficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin Van Tassell, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <phone>8048280513</phone>
    <email>aabbate@vcu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin W Van Tassell, PharmD</last_name>
    <phone>8049820997</phone>
    <email>bvantassell@vcu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Abbate, MD, PhD</last_name>
      <phone>804-828-0513</phone>
      <email>aabbate@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>Antonio Abbate, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Inflammation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
